Novo Nordisk

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 54,400 people in 80 countries and markets its products in around 170 countries. For more information visit novonordisk.com.

Our US Research & Development hub, located in the Greater Boston area, brings together the best talent to drive life science innovation. Located in Lexington, Watertown and Cambridge, our teams reflect the full scope of R&D, from early research through late-stage clinical development. We are building for the future by creating a distinct R&D community based on collaboration, partnerships, and cutting-edge research across multiple modalities and therapeutic areas. We recognize that improving human health starts here and that patients rely on us. By combining the speed and agility of biotech with the quality, resources, and stability of a large pharmaceutical company, our US R&D hub will benefit from the best of both worlds to develop new medicines that meet the needs of patients.

Novo Nordisk is its people. We rely on the diversity of perspectives from colleagues all around the world. Our forward thinking, supported by careers that are as dynamic as we are, makes Novo Nordisk a great place to be and be from. This is your moment. Here we don’t stand still, we never give up – we make an impact. We’re trusted to have the courage. Together, we make it happen.

  • 2025 BPTW Badge - RBG.png
  • 2024 Best Places to Work
75 Hayden Avenue
Lexington, MA 02421
  • Featured Employer
NEWS
FDA
The approval marks the first glucagon-like peptide-1 (GLP-1) receptor agonist approved for children and adolescents with type 2 diabetes.
Almost 15,000 physicians, scientists, health care professionals and industry representatives from around the globe presented research, treatment recommendations and advances toward a diabetes cure at the American Diabetes Association’s 79th Scientific Sessions in San Francisco this week.
“Over the past few years there has been a good amount of information presented at ADA. This year though, with all of the data presented, this was the most exciting year,” Todd Hobbs, U.S. chief medical officer of Novo Nordisk, told BioSpace in an exclusive interview.
Despite very positive results, the company’s shares were down 1.5% in premarket trading today. Vamil Divan, an analyst with Credite Suisse, wrote in a note to investors, that results “were fairly consistent across various patient subgroups and are clearly positive” for this class of drug, but “we believe investors may have been hoping for greater risk reduction.”
A Phase III trial compared Sanofi’s Soliqua/Suliqua to other GLP-1 receptor agonists (GLP-1 RA), with Soliqua showing a superior decrease of average blood sugar level (HbA1c) after 26 weeks.
The company announced a new target of achieving zero CO2 emissions from all operations and transport by 2030.
Novo Nordisk announced positive results from its ELLIPSE Phase III clinical trial of Victoza (liraglutide) in treating type 2 diabetes in children aged 10 to 17. The company presented the results at the Pediatric Endocrine Society (PES)/Pediatric Academic Societies (PAS) Annual Meeting held in Baltimore, MD, and simultaneously published in the New England Journal of Medicine.
The companies will collaborate on a clinical trial to combine Novo Nordisk’s semaglutide and Gilead’s cilofexor and firsocostat for treatment of NASH.
The study, which uses data gathered from Great Places to Work, points to the company’s openness from its leadership and the treatment of its employees as the primary reason it took the top spot.
JOBS
IN THE PRESS